The IPO launch party is up and at it early on a Monday morning. In this club we serve up \u00a0hot coffee and equity offerings.<\/p>\n
So far this morning a trio of biotech offerings launched:\u00a0Fusion Pharmaceuticals (FUSN)<\/strong>,\u00a0Akouos Inc (AKUS)\u00a0<\/strong>and\u00a0PolyPid Ltd. (PYPD)<\/strong><\/p>\n Company: Akouos, Inc. Company: Fusion Pharmaceuticals Inc. Company: PolyPid Ltd. One deal that we “anticipated” to launch was ArcherDX Inc (RCHR)<\/strong>, however, that company was acquired by Invitae Corporation (NVTA) in an announcement this morning.\u00a0<\/strong><\/a><\/p>\n These three IPOs are in addition to the Friday launches of Albertson’s Holding Company (ACI) and Agora Inc (API).\u00a0Additionally, a. $1.5bn equity raise by American Airlines Group (AAL) was announced. The offering features $750m worth of common shares and $750m worth of senior notes. IPO Boutique rates (BUY, Neutral or Avoid) only the common shares.<\/p>\n We use underwriting sources, buy-side contacts and statistical analysis to tackle the syndicate market. Give us a try for as little as $50 per week.<\/p>\n
\n
\nSymbol: AKUS
\nDescription: They are a precision genetic medicine company dedicated to our mission of developing gene therapies with the potential to restore, improve, and preserve high-acuity physiologic hearing for people worldwide who live with disabling hearing loss.
\nShares: 8.33 million
\nPrice Range: $16.00-$18.00
\nMarket Cap: $453m-$510m
\nTrade Date: Friday, 6\/26
\nUnderwriter(s): BofA Securities, Cowen, Piper Sandler
\nCo-Manager: BTIG
\nTerms Added: 6-22-20<\/p>\n
\nSymbol: FUSN
\nDescription: They are a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines.
\nShares: 8.35 million
\nPrice Range: $14.00-$16.00
\nMarket Cap: $525m-$600m
\nTrade Date: Friday, 6\/26
\nUnderwriter(s): Morgan Stanley, Jefferies, Cowen
\nCo-Manager: Wedbush PacGrow
\nTerms Added: 6-22-20
\n5% Buying by Insiders, Directors, Employees<\/p>\n
\nSymbol: PYPD
\nDescription: They are a Phase 3 clinical-stage biopharmaceutical company focused on developing targeted, locally administered and prolonged-release therapeutics using our proprietary Polymer-Lipid Encapsulation matriX, or PLEX, technology.
\nShares: 3.125 million
\nPrice Range: $15.00-$17.00
\nMarket Cap: $246m-$279m
\nTrade Date: Friday, 6\/26
\nUnderwriter(s): Barclays, BMO Capital
\nCo-Manager: Raymond James, National Securities, ODDO BHF, AGP
\nTerms Added: 6-22-20
\nLast Postponed in March 2018<\/p>\n
\n